ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > MD&A

<< Previous

Bullboard Posts

Next >>

Comment by goldtechon May 18, 2022 8:39pm

117 Views

Post# 34694209

RE:RE:RE:RE:RE:RE:RE:MD&A

Gene and Elliott had no plans to take this private and continually did cheap financing to steal money for themselves and get ridiculously cheap option shares. This pathetic board has no market savy and should have been replaced years ago. One thing they counted on was once they are voted in shareholders rarely dissent to change and are sheep. Live with what you voted for!!!!!!

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China